BACKGROUND: Multiple sclerosis (MS) and neuromyelitis optica (NMO) are immune-mediated inflammatory diseases of the central nervous system. In the acute phase of these diseases, secondary ischemia due to inflammation-induced endothelial dysfunction may be an important pathological change. Pentraxin 3 (PTX3) is a pro-inflammatory protein and a novel biomarker of inflammatory vascular diseases. OBJECTIVE: We aimed to determine whether PTX3 levels are elevated in MS and NMO patients. METHODS: The concentrations of plasma PTX3 were measured using an enzyme-linked immunosorbent assay in 22 MS patients, 26 NMO patients, 15 acute cerebral infarction (CI) patients, 11 mild headache patients, and 14 volunteer controls. RESULTS: During relapse, plasma PTX3 levels were higher in MS patients than in headache patients (p=0.003) and controls (p<0.001). Plasma PTX3 levels were also increased in NMO patients compared with CI patients (p=0.011), headache patients (p<0.001) and controls (p<0.001). CI patients showed elevated PTX3 levels compared with controls (p=0.008). MS and NMO patients showed a trend toward an increased disease disability with higher plasma PTX3 during relapse (MS: p=0.005; NMO: p<0.001). Plasma PTX3 levels were remarkably lower in remission than in the relapse stage (MS: p<0.001; NMO: p<0.001). CONCLUSION: Plasma PTX3 level is associated with inflammatory responses in MS and NMO.
BACKGROUND:Multiple sclerosis (MS) and neuromyelitis optica (NMO) are immune-mediated inflammatory diseases of the central nervous system. In the acute phase of these diseases, secondary ischemia due to inflammation-induced endothelial dysfunction may be an important pathological change. Pentraxin 3 (PTX3) is a pro-inflammatory protein and a novel biomarker of inflammatory vascular diseases. OBJECTIVE: We aimed to determine whether PTX3 levels are elevated in MS and NMO patients. METHODS: The concentrations of plasma PTX3 were measured using an enzyme-linked immunosorbent assay in 22 MSpatients, 26 NMO patients, 15 acute cerebral infarction (CI) patients, 11 mild headachepatients, and 14 volunteer controls. RESULTS: During relapse, plasma PTX3 levels were higher in MSpatients than in headachepatients (p=0.003) and controls (p<0.001). Plasma PTX3 levels were also increased in NMO patients compared with CI patients (p=0.011), headachepatients (p<0.001) and controls (p<0.001). CI patients showed elevated PTX3 levels compared with controls (p=0.008). MS and NMO patients showed a trend toward an increased disease disability with higher plasma PTX3 during relapse (MS: p=0.005; NMO: p<0.001). Plasma PTX3 levels were remarkably lower in remission than in the relapse stage (MS: p<0.001; NMO: p<0.001). CONCLUSION: Plasma PTX3 level is associated with inflammatory responses in MS and NMO.
Authors: Kimberly M Anderson; C Jane Welsh; Colin Young; Gwendolyn J Levine; Sharon C Kerwin; C Elizabeth Boudreau; Ismael Reyes; Armando Mondragon; John F Griffin; Noah D Cohen; Jonathan M Levine Journal: J Neurotrauma Date: 2015-07-17 Impact factor: 5.269
Authors: Mustafa Serdar Sağ; Sinem Sağ; İbrahim Tekeoğlu; Ayhan Kamanli; Kemal Nas; Halil Harman Journal: Arch Rheumatol Date: 2017-09-13 Impact factor: 1.472